Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218785 | 0.89 | ACHE (0.48) | ACHEHTR2CHTR2AHTR2BMAOA | |
| Hydrochloric Acid SCHEMBL4866638 | 0.88 | ACHE (0.47) | ACHEHTR2CHTR2AHTR2BMAOA | |
| SCHEMBL11701223 | 0.83 | PARP1 (0.40) | PARP1ACHECA1CA2ALDH1A1 | |
| SCHEMBL4947260 | 0.81 | PARP1 (0.39) | PARP1ACHEHTR2CCA12CA1 | |
| SCHEMBL1536877 | 0.79 | ALDH1A1 (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL7096437 | 0.78 | PRNP (0.36) | PARP1CA12CA1CA2CA9 | |
| SCHEMBL3941319 | 0.76 | ACHE (0.41) | PARP1ACHEALDH1A1HSD17B10KDM4E | |
| SCHEMBL22412071 | 0.75 | KDM4E (0.39) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10912290 | 0.75 | MEN1 (0.39) | HTR2CHTR2AHTR2BCA12CA1 | |
| SCHEMBL12525237 | 0.75 | HTR2A (0.40) | PARP1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319100-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-7205306-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1392309-B1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1392309-A4 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1392309-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030171380-A1 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-09-11 | — | — | US | disclosed |
| WO-2002092090-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171380-A1 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | CRH, CRHR1, CRHR2 | PARP1 3808/4885ACHE 3779/4885HTR2C 28/4885 |
| US-20070155740-A1 | SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS | CRH, CRHR1, CRHR2 | PARP1 3794/4885ACHE 3706/4885HTR2C 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.